The Health Resources and Services Administration (HRSA) has sent letters to six pharmaceutical companies — AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics — letting them know their failure to comply with the 340B drug discount program has been referred to the Office of Inspector General at HHS. And several of the companies are pushing back.